That was weird, page-15

Yep, the latest info I got from management was that child pneumonia and asthma would be the first submission to FDA, then rolling submissions every few months for other diseases and for adults.

So after the first approval for two diseases, there will be a new disease approved every two months, which will be great for newsflow. Investors will develop an expectation of rolling approvals. That's the plan, anyway. After the top 10 respiratory diseases are done, I assume the speed of approvals will slow down for the rarer diseases because it's harder to get good samples sizes.